Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Agilent spends $725M to expand manufacturing

By Chris Newmarker | January 10, 2023

Agilent logoAgilent recently announced that it plans to double its manufacturing capacity of therapeutic nucleic acids.

The $725 million investment will go toward the Santa Clara, California–based company’s Frederick, Colorado facility. The Colorado plant will get new Train C and D manufacturing lines. The facility already has a Train B manufacturing line, announced in 2020, that will go live later this year.

The expanded facility will include advanced automation and engineering enhancements such as water reduction and solvent capturing and recycling.

Therapeutic nucleic acids represent a rapidly growing $1 billion market, according to Agilent. In addition, there is strong demand for the company’s high-quality active pharmaceutical ingredients (API). The new lines in Colorado will enable the company to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to start in 2026.

“This investment reflects not only the strong demand for therapeutic oligos, but also for the unmatched quality and service of our therapeutic oligo contract development and manufacturing organization (CDMO),” Agilent CEO Mike McMullen said in a news release. “It’s yet another example of our focus on investing in high-growth markets while also delivering on Agilent’s mission of improving the quality of life.”

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE